Sava Technologies completed a $19 million Series A funding round to develop its multi-molecule biosensor capable of real-time biomarker detection beneath the skin. The investment will accelerate the launch of its continuous glucose monitor, which demonstrated promising accuracy over a 10-day wear period in early clinical data. This innovation aims to improve wearable health monitoring by providing precise, minimally invasive glucose readings.